<div id="readability-page-1"><div><p>While maintaining its &#34;outperform&#34; opinion on Moderna shares, Oddo BHF has lowered its target price for them from $51 to $47, following the discontinuation of its clinical program for cytomegalovirus after negative results from its Phase 3 study.</p><p> The discontinuation of the program does not impact the group's annual guidance and does not call into question its medium-term objective of achieving financial equilibrium by 2028. However, the discontinuation of this asset at an advanced stage is likely to penalize the stock today,&#34; the analyst warns. </p><p>&#34;Moderna's challenge remains to diversify its topline. We are therefore incorporating this discontinuation into our estimates and removing the contribution of the CMV vaccine from our projections (the program represented $4 per share in our SOP),&#34; he continues.</p></div></div>

MRNA

<p>Oddo BHF has lowered its target price for Moderna shares from $51 to $47 while maintaining an "outperform" rating. This adjustment follows the discontinuation of its cytomegalovirus clinical program after negative Phase 3 results. Despite this setback, the group's annual guidance remains unchanged, and its medium-term goal of achieving financial equilibrium by 2028 is still intact. However, the analyst notes that this discontinuation may negatively impact the stock today, as it removes a projected $4 per share contribution from the CMV vaccine.</p>

Moderna: Oddo BHF lowers target price